PIONEERING PRECISION IN
|
|
|
|
At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescent biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals. |
PHOTONIC PHARMA NEWS:
- February 28, 2026: Photonic Pharma completed the subaward on our fourth NIH grant.
- March 31, 2026: after nearly twelve years of business, Photonic Pharma has donated our proprietary plate readers (FLT-PR and SUPR - see Instruments page) to the University of Minnesota. The instruments will continue to be available to users at the Biophysical Technology Center (for reservations click here)